The trademark application ZYGFLOVI was filed by Direct Biologics LLC, a Limited Liability Company (the "Applicant"). The application was published for oppositions on August 27, 2024, and still open for oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with Pharmaceutical preparations based upon human allogeneic bone marrow mesenchymal stem cell derived extracellular vesicles (EVs) containing secretomes for the treatment of immunomodulatory, inflammatory, or autoimmune conditions such as respiratory diseases, neurological diseases, tissue injury and repair, gastrointestinal diseases, joint diseases and transplant.